In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Movetis NV

Division of Takeda Pharmaceutical Co. Ltd.
www.movetis.com

Latest From Movetis NV

The New Zelnorm-al (Part 2): More Thoughts On The Revival Of The 5HT4 Class

Looming return of Zelnorm to US market is milestone event for current regulatory climate. But FDA’s hands-on work to resurrect a different 5HT4 agonist, prucalopride, probably says more about what is truly different about the agency today.
Drug Approval Standards Drug Safety

VCs Back ObsEva With $35M For Trials On Pre-term Labor Drug

The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.

BioPharmaceutical Europe

Cardio3 and Cellular Dynamics join IPO hopefuls

Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs).

Cardiovascular Cancer

Shire faces RoI test under vision-loving new CEO

Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions in ophthalmology, an area in which he has specialized. However, with many recent acquisitions yet to mature to revenue-generation, and with big indication areas for Shire like ADHD at risk from generic and branded competition, the pressure is on the new CEO – even before he officially starts work.

Gastrointestinal
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Dirk Reyn, CEO
    Catherine Moukheibir, CFO
    Lieve Vandeplassche, PhD, Chief Dev. Officer
    Jan Schuurkes, PhD, CSO
    Bertrand Verwee, VP, Mktg.
  • Contact Info
  • Movetis NV
    Phone: (32) 14 404 390
    Veedijk 58 (1004)
    Turnhout, 2300
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register